Abstract 13083: Lipoprotein(a) is a Residual Cardiovascular Risk Factor in Statin Treated Stroke Survivors - Insights From the SPARCL Trial

IntroductionElevated lipoprotein (a) [Lp(a)] plasma levels are causally associated with CAD. The association between Lp(a) and stroke is however less clear. The SPARCL trial has demonstrated the superiority of 80mg atorvastatin to placebo for the prevention of stroke in patients with recent stroke o...

Full description

Saved in:
Bibliographic Details
Published in:Circulation (New York, N.Y.) N.Y.), 2022-11, Vol.146 (Suppl_1), p.A13083-A13083
Main Authors: Chemello, Kevin, Gallo, Antonio, Lambert, Gilles
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:IntroductionElevated lipoprotein (a) [Lp(a)] plasma levels are causally associated with CAD. The association between Lp(a) and stroke is however less clear. The SPARCL trial has demonstrated the superiority of 80mg atorvastatin to placebo for the prevention of stroke in patients with recent stroke or TIA. The aim of the current study was to investigate if Lp(a) is predictive of recurrent cerebrovascular and incident coronary events in these patients. MethodsLp(a) concentration and apolipoprotein(a) [apo(a)] isoform size, a strong determinant of Lp(a) plasma levels, were measured by LC-HRMS in samples collected at baseline from 2814 SPARCL participants (1418 randomized to atorvastatin & 1396 to placebo). Within each treatment arm, we compared patients in the highest quartile (>84.0nmol/L) with those in the lowest quartiles of Lp(a) concentrations and patients in the lowest quartile (
ISSN:0009-7322
1524-4539
DOI:10.1161/circ.146.suppl_1.13083